{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:07:32Z","timestamp":1792868852998,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N910D00024"],"award-info":[{"award-number":["75N910D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clim.2024.110400","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T18:06:19Z","timestamp":1731866779000},"page":"110400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): Adolescent and adult subgroup analysis"],"prefix":"10.1016","volume":"270","author":[{"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0160ediv\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.S.H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Plebani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Trizzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Zharankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanvin","family":"Orpia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kulm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"K\u00f6rholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Lougaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Rodina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bradt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Relan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2024.110400_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13223-020-00420-6","article-title":"Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys","volume":"16","author":"Ewertowska","year":"2020","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0015","first-page":"9","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u03b4 syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase \u03b4 syndrome registry","author":"Maccari","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10238-023-01259-y","article-title":"Systematic review of mortality and survival rates for APDS","volume":"24","author":"Hanson","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.clim.2024.110400_bb0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2; a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0035","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Reviews Allergy Immunol"},{"key":"10.1016\/j.clim.2024.110400_bb0050","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.immuni.2006.08.015","article-title":"Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling","volume":"25","author":"Omori","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2024.110400_bb0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1525-1497.2003.21246.x","article-title":"Health-related quality of life of adults with upper respiratory tract infections","volume":"18","author":"Linder","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.clim.2024.110400_bb0065","unstructured":"APDS - Activated PI3K Delta Syndrome. 2020. Avaliable from: https:\/\/ipopi.org\/wp-content\/uploads\/2020\/06\/WEB_APDS.pdf. [Last accessed: 6th November 2024]. International Patient Organisation for Primary Immunodeficiencies."},{"key":"10.1016\/j.clim.2024.110400_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2020.11.018","article-title":"Burden of recurrent pericarditis on health-related quality of life","volume":"141","author":"LeWinter","year":"2020","journal-title":"American J Cardiol"},{"key":"10.1016\/j.clim.2024.110400_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13023-024-03215-9","article-title":"A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS)","volume":"19","author":"Hitchcock","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2024.110400_bb0080","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3K\u03b4 syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0090","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d\u2013targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clim.2024.110400_bb0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clim.2024.110400_bb0100","unstructured":"FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome. 2023. Avaliable from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome. [Last accessed: 6th November 2024]. FDA."},{"key":"10.1016\/j.clim.2024.110400_bb0105","unstructured":"Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union. 2024. Avaliable at: https:\/\/www.pharming.com\/sites\/default\/files\/imce\/Press%20releases\/Pharming%20Group%20announces%20EU%20regulatory%20update_EN_30MAY24.pdf. [Last accessed: 6th November 2024]. Pharming."},{"key":"10.1016\/j.clim.2024.110400_bb0110","unstructured":"MHRA approves first medicine for rare immune disease APDS. 2024. Avaliable at: https:\/\/www.gov.uk\/government\/news\/mhra-approves-first-medicine-for-rare-immune-disease-apds#:\u223c:text=The%20Medicines%20and%20Healthcare%20products,who%20weigh%2045kg%20or%20more. [Last accessed: 6th November 2024]. Gov.UK."},{"key":"10.1016\/j.clim.2024.110400_bb0115","doi-asserted-by":"crossref","first-page":"1208567","DOI":"10.3389\/fimmu.2023.1208567","article-title":"Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment","volume":"14","author":"Vanselow","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2009.05.020","article-title":"Refined characterization and reference values of the pediatric T- and B-cell compartments","volume":"133","author":"van Gent","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2024.110400_bb0130","unstructured":"Common Terminology Criteria for Adverse Events Version 5.0. 2017. Avaliable from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. [Last accessed: 6th November 2024]. U.S. Department of Health and Human Services."},{"key":"10.1016\/j.clim.2024.110400_bb0135","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10875-022-01207-7","article-title":"Psychological symptoms in primary immunodeficiencies: a common comorbidity?","volume":"42","author":"Manusama","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110400_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.18773\/austprescr.2017.053","article-title":"Drug dosing in obese adults","volume":"40","author":"Barras","year":"2017","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.clim.2024.110400_bb0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2024.110400_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/25785826.2023.2210366","article-title":"Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan","volume":"43","author":"Moriya","year":"2023","journal-title":"Immunol Med"},{"key":"10.1016\/j.clim.2024.110400_bb0155","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and safety of PI3K inhibitors in cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.clim.2024.110400_bb0160","series-title":"Pediatric patients aged 4 to 11 years with APDS (NCT05438407)","year":"2023"},{"key":"10.1016\/j.clim.2024.110400_bb0165","series-title":"Pediatric patients aged 1 to 6 years with APDS (NCT05693129)","year":"2023"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624005096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624005096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T15:04:55Z","timestamp":1733670295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624005096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["S1521661624005096"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110400","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): Adolescent and adult subgroup analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110400"}}